ANGLE plc is delighted to announce that its first bespoke assay development customer, Artios Pharma, has signed a new contract to utilise two DNA Damage Response assays developed by ANGLE in a Phase 1 clinical trial expected to commence shortly.
ANGLE plc is delighted to announce that its first bespoke assay development customer, Artios Pharma, has signed a new contract to utilise two DNA Damage Response assays developed by ANGLE in a Phase 1 clinical trial expected to commence shortly.